证券代码：301393 证券简称：昊帆生物 公告编号：2024-032 苏州昊帆生物股份有限公司 1 本框架协议为各方友好协商达成的投资意向协议，公司将在具体事项明确后， 按照《深圳证券交易所创业板股票上市规则》和《公司章程》等相关规定，根据 投资事项的进展履行相应的决策程序和信息披露义务。 关于签署投资框架协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次签署的投资框架协议的项目产能、投资金额、建设周期、土地面积 等均为预计数，相关事项存在一定的不确定性，不构成对投资者的承诺。具体事 项明确后，尚须经公司董事会或股东大会（如需）审议决议通过后方可生效（可 根据投资规模与进度分期提交审议，分期生效后实施）。 2、本次签订投资协议的行为不构成关联交易，亦不构成《上市公司重大资 产重组管理办法》中规定的重大资产重组。 3、本次协议的签署对公司当期经营和业绩不产生重大影响，项目建设周期 较长，对未来公司财务状况及经营成果的影响尚不确定。 4、本次投资项目的实施尚需政府部门立项核准及报备、环评审批和施工许 可等前置审批手续，如因国家或地方 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 苏州昊帆生物股份有限公司（以下简称"公司"）于 2024 年 4 月 7 日召开第 三届董事会第十三次会议及第三届监事会第十三次会议，并于 2024 年 5 月 10 日召开 2023 年度股东大会，审议通过了《关于使用闲置募集资金进行现金管理 的议案》，同意公司使用额度不超过 8 亿元的闲置募集资金进行现金管理。使用 期限自股东大会审议通过之日起 12 个月内有效。在前述额度和期限内，资金可 以循环滚动使用，闲置募集资金现金管理到期后将及时归还至募集资金专户。具 体内容详见公司于 2024 年 4 月 9 日在巨潮资讯网（www.cninfo.com.cn）披露的 《关于使用闲置募集资金进行现金管理的公告》（公告编号：2024-016）。 近日，公司全资子公司安徽昊帆生物有限公司开立了闲置募集资金现金管理 专用结算账户，具体如下： | 安徽昊帆生物有限公司 | 86021110000238791 | 宁波银行苏州高新技术产业 | | --- | --- | --- | | 账户名称 | 账号 | 开户机构 开发 ...

证券代码：301393 证券简称：昊帆生物 公告编号：2024-031 一、股东大会审议通过利润分配方案情况 1、公司 2023 年度股东大会审议通过了公司 2023 年度利润分配方案，具体 如下：以实施权益分派股权登记日登记的公司股份总数 108,000,000 股扣减公司 回购专用证券账户中的股份为基数，向全体股东按每 10 股派发现金股利人民币 2.50 元（含税），不送红股，不进行资本公积金转增股本。在利润分配预案披露 日至实施权益分配股权登记日期间，因新增股份上市、股权激励授予或行权、可 转债转股、股份回购等事项导致公司股本发生变动的，公司将维持分配比例不变， 1 苏州昊帆生物股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、苏州昊帆生物股份有限公司（以下简称"公司"）回购专用证券账户中的 股份 715,048 股不参与本次权益分派。本次权益分派将以公司现有总股本 108,000,000 股剔除已回购股份 715,048 股后的 107,284,952 股为基数，向全体股 东每 10 股派 ...

上海市广发律师事务所 关于苏州昊帆生物股份有限公司 2023 年度股东大会的法律意见书 致：苏州昊帆生物股份有限公司 苏州昊帆生物股份有限公司（以下简称"公司"）2023 年度股东大会于 2024 年 5 月 10 日在江苏省苏州高新区长亭路 1 号公司会议室召开。上海市广发律师 事务所经公司聘请，委派何晓恬律师、吉喆律师出席本次会议，根据《中华人民 共和国公司法》（以下简称"《公司法》"）、《上市公司股东大会规则》（以下简称 "《股东大会规则》"）等法律法规、其他规范性文件以及《苏州昊帆生物股份有 限公司章程》（以下简称"《公司章程》"）的规定，就本次股东大会的召集和召开 程序、召集人及出席会议人员的资格、会议议案、表决方式和表决程序、表决结 果和会议决议等出具本法律意见书。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 公司已向本所保证和承诺，公司向本所律师所提供的文件和所作的陈述和说 明是完整的、真实的和有效的，有关原件及其上面的签字和印章是真实的，且一 切足以影响本法律意见书的事实和文件均已向本所披露，而无任何隐瞒、疏 ...

证券代码：301393 证券简称：昊帆生物 公告编号：2024-030 苏州昊帆生物股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议时间： （1）现场会议召开日期：2024 年 5 月 10 日（星期五）下午 2 时 30 分 （2）互联网投票时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为: 2024 年 5 月 10 日 9:15—9:25，9:30—11:30，13:00—15:00; ②通过深圳证券交易所互联网投票系统进行网络投票的具体时间为: 2024年 5 月 10 日 9:15—15:00。 2、会议地点：江苏省苏州高新区长亭路 1 号，昊帆生物会议室 5、会议主持人：董事长朱勇先生 6、本次会议符合《中华人民共和国公司法》和《苏州昊帆生物股份有限公 司章程》等有关规定，会议合法有效。 7、股东出席的总体情况： 参加本次股东大会表决的股东和股东代表（ ...

证券代码：301393 证券简称：昊帆生物 公告编号：2024-029 截至 2024 年 4 月 30 日，公司通过回购专用证券账户以集中竞价交易方式累 计回购公司股份 715,048 股，占公司目前总股本的 0.66%，最高成交价为 51.50 元/股，最低成交价为 36.77 元/股，成交总金额为 30,181,482.68 元（不含交易费 用）。公司回购股份的实施符合相关法律、法规、规范性文件及公司股份回购方 案的规定。 二、其他说明 公司回购股份的时间、回购股份数量及集中竞价交易的委托时段等符合《深 圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定。 1、公司未在下列期间回购公司股票： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； 苏州昊帆生物股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 苏州昊帆生物股份有限公司（以下简称"公司"）于 2024 年 2 月 5 日召开第 三届董事会第十二次会议及第三届监事会第十二次会议，审 ...

Financial Performance - Revenue for Q1 2024 was ¥91,229,728.71, a decrease of 27.14% compared to ¥125,210,000.82 in the same period last year[5] - Net profit attributable to shareholders was ¥29,828,839.74, down 17.80% from ¥36,288,001.96 year-over-year[5] - Net profit excluding non-recurring items was ¥25,769,764.03, reflecting a decline of 24.12% from ¥33,960,792.95 in the previous year[5] - Basic and diluted earnings per share decreased to ¥0.28, down 37.78% from ¥0.45 in the prior year[5] - Total operating revenue for Q1 2024 was CNY 91,229,728.71, a decrease of 27.1% compared to CNY 125,210,000.82 in the same period last year[24] - Net profit for Q1 2024 was CNY 29,828,839.74, a decline of 17.7% from CNY 36,288,001.96 in Q1 2023[25] Cash Flow and Liquidity - Operating cash flow improved significantly, with a net cash flow from operating activities of ¥23,295,794.97, compared to a negative cash flow of ¥11,994,516.75 in the same quarter last year, marking a 294.22% increase[5] - Cash and cash equivalents at the end of the reporting period amount to 1,734,899,973.95 RMB, slightly down from 1,739,510,856.63 RMB at the beginning of the period[20] - Cash flow from investment activities was negative at -$22,411,271.01, an improvement from -$45,816,287.92 in the previous period[28] - Cash flow from financing activities also showed a negative trend at -$9,629,027.59, compared to -$658,849.75 previously[28] - The ending cash and cash equivalents balance was $1,246,675,971.66, a decrease from $1,255,236,454.77 at the beginning of the period[28] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,312,149,453.18, a slight increase of 1.10% from ¥2,286,941,939.28 at the end of the previous year[5] - Total liabilities for Q1 2024 were CNY 79,605,794.21, up from CNY 75,077,619.91 in Q1 2023[22] - Cash and cash equivalents increased to CNY 1,981,489,807.37 from CNY 1,964,007,891.97 year-over-year[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,434[12] - The largest shareholder, Zhu Yong, holds 47.40% of shares, totaling 51,192,000 shares[12] - The company plans to repurchase shares with a total amount not less than 30 million RMB and not exceeding 60 million RMB, with a maximum repurchase price of 60 RMB per share[17] - As of March 31, 2024, the company has repurchased 200,000 shares, accounting for 0.19% of the total share capital, with a total transaction amount of 9,432,971 RMB[18] Research and Development - Research and development expenses surged by 122.67% to ¥10,389,895.99, primarily due to an increase in R&D personnel[9] - Research and development expenses for Q1 2024 were CNY 10,389,895.99, significantly higher than CNY 4,665,960.48 in Q1 2023, indicating increased investment in innovation[24] Financial Management - Interest income skyrocketed by 8,561.83% to ¥12,439,672.85, attributed to cash management of idle raised funds[9] - The company reported a financial income of CNY 12,439,672.85 in Q1 2024, compared to CNY 143,614.88 in the same period last year, reflecting improved financial management[25] - The company received government subsidies totaling ¥4,500,000.00, contributing positively to its financial performance[7] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]

证券代码：301393 证券简称：昊帆生物 公告编号：2024-027 苏州昊帆生物股份有限公司 4、会议召开的日期、时间： （1）现场会议召开日期：2024 年 5 月 10 日（星期五）下午 2 时 30 分 （2）互联网投票时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 5 月 10 日 9:15—9:25，9:30—11:30，13:00—15:00; 关于召开 2023 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 苏州昊帆生物股份有限公司于 2024 年 4 月 9 日在中国证监会指定的创业板 信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露了《关于召开 2023 年度 股东大会的通知》（公告编号：2024-021）。本次股东大会采用现场表决与网络投 票相结合的方式召开，现将本次股东大会的有关事宜提示如下： 一、召开会议的基本情况 1、股东大会届次：2023 年度股东大会。 2、股东大会的召集人：苏州昊帆生物股份有限公司（以下简称"公司"）第三 届董事会第十三次会议决议提请召 ...

医药生物/生物制品 昊帆生物（301393.SZ） 2024 年 04 月 11 日 业绩阶段性承压，自有产能逐步落地赋能中长期发展 ——公司信息更新报告 核心产品具有较强的市场竞争力，自有产能建设快速推进 风险提示：国内政策变动，核心人才流失，行业需求下降等。 股价走势图 《收入端环比改善，下游需求释放助 力中长期发展—公司信息更新报告》 -2023.10.29 | --- | --- | |-------------------------|--------------| | 日期 | 2024/4/11 | | 当前股价 ( 元 ) | 42.55 | | 一年最高最低 ( 元 ) | 118.88/36.51 | | 总市值 ( 亿元 ) | 45.95 | | 流通市值 ( 亿元 ) | 10.52 | | 总股本 ( 亿股 ) | 1.08 | | 流通股本 ( 亿股 ) | 0.25 | | 近 3 个月换手率 (%) | 558.92 | f 隔证券 公 司 研 究 余汝意（分析师） 汪晋（联系人） yuruyi@kysec.cn wangjin3@kysec.cn 证书编号：S0790523 ...

Financial Performance - Net profit for the current period is ¥98,973,754.53, a decrease of 23.5% compared to ¥129,370,943.06 in the previous period[50]. - Cash flow from operating activities for the current period is ¥87,829,868.67, down 36.6% from ¥138,673,297.82 in the previous period[50]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in the last fiscal year, representing a growth of 15% year-over-year[119]. - Total operating revenue for 2023 was ¥388,794,947.08, a decrease of 13.1% compared to ¥447,457,811.11 in 2022[182]. - Basic and diluted earnings per share for 2023 were both ¥1.07, compared to ¥1.60 in 2022[183]. - The total equity increased to ¥2,129,084,007.67 in 2023 from ¥451,253,592.59 in 2022, showing a growth of 372%[182]. Research and Development - The company aims to develop new products, including liposome and lipid nanoparticle reagents, ionic liquids, PROTAC reagents, and nucleotide reagents, to meet customer demands and enhance its market position[27]. - The company emphasizes research and development as a priority, aiming to provide specialized chemical raw materials with higher synthesis technology barriers to support the pharmaceutical industry[28]. - The company has been granted 7 new invention patents in 2023, bringing the total to 38 patents, including 34 invention patents and 4 utility model patents[29]. - The company is investing heavily in R&D, with 150 million allocated for new technology development, aiming to enhance product efficiency and effectiveness[123]. - The company has engaged in various research projects, including over 120 published research papers and more than 30 authorized invention patents[100]. Production and Operations - The company plans to enhance production capacity and expand its product line, focusing on the construction of the Anhui Haofan production base project and potentially acquiring additional production bases[22]. - The company maintains a focus on optimizing production processes and developing new product technologies to enhance operational efficiency[28]. - The company has implemented a quality management system compliant with ISO9001 standards, ensuring stable production processes and reliable product quality[30]. - The company has a strong emphasis on sustainable development supported by its robust synthesis technology reserves[29]. Financial Position - The total current assets as of December 31, 2023, reached approximately CNY 1.96 billion, a significant increase from CNY 352.67 million at the beginning of the year, reflecting a growth of over 455%[163]. - Cash and cash equivalents amounted to CNY 1.74 billion, up from CNY 99.32 million, indicating a growth of approximately 1,754%[163]. - The company's fixed assets increased to CNY 212.35 million from CNY 116.78 million, representing an increase of about 81.8%[166]. - The total liabilities amounted to ¥46,461,176.10 in 2023, compared to ¥103,735,086.64 in 2022, indicating a significant reduction[182]. Market Strategy - The company plans to expand its market presence and enhance its product offerings through ongoing research and development initiatives[100]. - Market expansion plans include entering two new international markets, projected to increase market share by 5%[126]. - The company is considering strategic acquisitions to bolster its market position, with a budget of up to 300 million for potential targets[126]. - Future guidance indicates a focus on increasing operational efficiency and expanding into new markets, with specific targets to be outlined in subsequent reports[153]. Corporate Governance - The company has established a structured and efficient corporate governance framework, enhancing operational efficiency through clear responsibilities among various governance bodies[31]. - The company has engaged in discussions to enhance decision-making processes, ensuring the interests of minority shareholders are considered[63]. - The board of directors did not raise any objections regarding company matters during the reporting period, indicating a unified leadership approach[115]. - The company has established a compensation and assessment committee to determine the remuneration of directors and senior management based on internal policies[103]. Shareholder Information - The company’s major shareholder remains unchanged during the reporting period, with no new changes in control[82]. - The actual controller, Zhu Yong, holds a 48.04% stake in the company, ensuring significant influence over corporate decisions[149]. - The company has not conducted any repurchase transactions among the top ten shareholders during the reporting period[84].